Myeloma

Myeloma cells
#Arcellx #ASH 2025 #Myeloma

Anito-cel could be ‘significant’ treatment for myeloma 

Biotechnology company Arcellx has announced positive data from the Phase II study of anitocabtagene autoleucel (anito-cel) in patients with relapsed or refractory multiple myeloma (RRMM).  Results from the iMMagine-1 study demonstrate deep and durable responses with a predictable and manageable safety profile in a fourth-line or higher (4L+) RRMM population,… Read More

#Cancer Research #News

Multiple myeloma
#Myeloma #National Institute for Health and Care Excellence (NICE) #NHS

NICE recommends myeloma treatment for NHS patients

The National Institute for Health and Care Excellence (NICE) has recommended Talvey (talquetamab) for use in the NHS for treating relapsed or refractory myeloma (RRMM) in adults.  Talquetamab, developed by Johnson & Johnson, is a first-in-class bispecific antibody targeting the GPRC5D receptor on myeloma cells. The treatment redirects T-cells to… Read More

#News #Regulatory

Multiple myeloma
#Clinical trial #FDA #Myeloma

FDA grants Fast Track Designation to myeloma treatment HDP-101

The US Food and Drug Administration has granted Fast Track Designation to myeloma candidate HDP-101 from Heidelberg Pharma.  The designation was supported by nonclinical data as well as clinical data from the ongoing Phase I/IIa study with HDP-101, evaluating the safety and antitumour activity of the candidate in patients with… Read More

#News #Regulatory

Myeloma cells
#Clinical trial #Myeloma

Phase I/IIa trial of myeloma treatment HDP-101 underway

The Phase I/IIa trial of HDP-101, an ATAC candidate for the treatment of relapsed or refractory multiple myeloma, is underway, biotech company Heidelberg Pharma has announced.  The Phase I/IIa trial will evaluate Cohort 9 of HDP-101 after the Safety Review Committee (SRC) confirmed that the 140 µg/kg dose… Read More

#News

Multiple myeloma
#Clinical trial #Myeloma

ACT appointed to conduct Phase IIa trial of POLB 001 

Specialist blood cancer trials organisation Accelerating Clinical Trials Limited (ACT) has signed an agreement with biopharmaceutical company Poolbeg Pharma to conduct the Phase IIa clinical trial of POLB 001.  The Phase IIa first-in-patient open-label, single-arm trial is titled TOPICAL (Trial of Prevention of ImmunoCytokine Adverse events in Myeloma). Read More

#News

Monoclonal antibodies
#FDA #Haematology #Myeloma #Oncology #Orphan drugs #Sanofi

Sanofi’s antibody earns orphan status for multiple myeloma

The US Food and Drug Administration (FDA) has granted orphan drug designation to SAR446523, an IgG1-based Antibody-Dependent Cellular Cytotoxicity-enhanced (ADCC) monoclonal antibody (mAb).  The mAb targets G-protein coupled receptor family C group 5 member D (GPRC5D) for the potential treatment of patients with relapsed or refractory multiple myeloma (R/R MM).  … Read More

#Cancer Research #News #Regulatory

Multiple myeloma
#FDA #GSK #Monoclonal antibodies #Myeloma #Oncology

FDA committee votes against Blenrep combinations for myeloma

The US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) has voted against the overall benefit/risk profile at GSK’s proposed dosage of Blenrep (belantamab mafodotin-blmf) combinations.   The belantamab mafodotin combinations were evaluated in adults with relapsed or refractory multiple myeloma who have received at least one prior line… Read More

#News #Regulatory

Multiple myeloma
#GSK #Japan #Myeloma #Oncology

Blenrep combinations approved in Japan for multiple myeloma

Blenrep combinations have been approved by Japan’s Ministry of Health, Labour and Welfare (MHLW) for the treatment of adults with relapsed or refractory multiple myeloma.  The approval follows an orphan drug designation for Blenrep in Japan, which was granted based on its ability to address high unmet need for patients… Read More

#News #Regulatory

Multiple myeloma
#Japan #Myeloma #Phase III trial #Regulatory #Sanofi

Sarclisa approved in Japan for newly diagnosed multiple myeloma

The Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Sarclisa, in combination with bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment of adult patients with newly diagnosed multiple myeloma (NDMM) based on data from the IMROZ Phase III study.  Olivier Nataf, Global Head of Oncology at Sanofi,… Read More

#News #Regulatory

Myeloma cells
#Genetics #Myeloma #Oncology #Personalised medicine #The Institute of Cancer Research

Personalised treatment needed for high-risk myeloma, say scientists

Offering genetic testing to patients with myeloma would help doctors spot those with the most aggressive forms of the disease so that their cancer can be targeted more effectively, say scientists.  With effective treatment, more than half of myeloma patients will survive their disease for five years… Read More

#Cancer Research #Editor's Choice #News

The European Medicines Agency in Amsterdam
#European Commission #Monoclonal antibodies #Myeloma #Oncology #Sanofi

EU extends Sarclisa use to newly diagnosed multiple myeloma

Following the adoption of a positive opinion by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), the EU has now approved Sanofi’s monoclonal antibody Sarclisa (isatuximab).  It is approved in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment of adult… Read More

#News #Regulatory

Multiple myeloma
#Antibody drug conjugate (ADC) #Clinical trials #Heidelberg Pharma #Myeloma

Heidelberg Pharma progresses multiple myeloma ADC

Heidelberg Pharma is advancing into Cohort 7 in a Phase I/IIa dose escalation study with lead ATAC candidate HDP-101 for the treatment of relapsed or refractory multiple myeloma. Heidelberg uses the compound Amanitin from the green death cap mushroom in cancer therapy. The biological mechanism of action of the toxin… Read More

#News

CAR-T in multiple myeloma
#CAR-T #Cell therapy #EsoBiotec #In vivo #Myeloma #Pregene Biopharma

In vivo BCMA CAR-T candidate shows promise in first human trial

EsoBiotec and Pregene Biopharma have dosed the first patient in an investigator-initiated clinical trial in China of ESO-T01 for relapsed/refractory multiple myeloma.   ESO-T01 is an immune shielded lentiviral vector that reprograms T lymphocytes in vivo into highly effective BCMA CAR-T cells.  The clinical… Read More

#Cancer Research #News

CAR-T therapy
#CAR-T #Cell therapy #EsoBiotec #In vivo #Myeloma #Phase I trial

First in vivo BCMA CAR-T candidate reaches the clinic

A clinical trial has launched in China of ESO-T01, an immune shielded lentiviral vector that reprograms T lymphocytes in vivo into BCMA CAR-T cells, for the treatment of multiple myeloma.  The proof-of-concept, first-in-human trial is underway and initial clinical data are expected to be presented… Read More

#Editor's Choice #News

CAR T-cells attacking a cancer cell
#CAR-T #Haematology #Myeloma #Oncology #Phase I trial #Poseida Therapeutics #Roche

Patients show 91% response to allogeneic CAR-T therapy

Investigators saw a 91% overall response rate (ORR) in patients with relapsed/refractory multiple myeloma (RRMM) following treatment with allogeneic CAR-T therapy P-BCMA-ALLO1 and lymphodepletion. The interim data from an ongoing Phase I trial in patients who have previously received three or more prior lines of therapy… Read More

#Cancer Research #News

FDA headquarters
#FDA #Monoclonal antibodies #Myeloma #Oncology #Sanofi

FDA approves Sarclisa combination for multiple myeloma

The US Food and Drug Administration (FDA) has approved Sanofi’s anti-CD38 monoclonal antibody isatuximab-irfc (Sarclisa) for newly diagnosed multiple myeloma. It is approved in combination with bortezomib, lenalidomide, and dexamethasone for adults with who are not eligible for autologous stem cell transplant (ASCT). The efficacy of the treatment was evaluated… Read More

#News #Regulatory